“ Compound 10” (AstraZeneca) is an oral CDK5-mediated PPARγ phosphorylation inhibitor and partial PPARγ agonist being developed as an antidiabetic drug . Although widely used PPARγ agonists such as rosiglitazone and pioglitazone are effective antidiabetics, they are limited by their side effects which have been attributed to PPARγ [...]
3 minute read
Apr. 19, 2022
An Oral CDK5-Mediated PPARγ Phosphorylation Inhibitor
compound 10
oral PPARg phosphorylation inhibitor, partial agonist efficacy in diabetic mouse model from structure-based virtual screen ACS Med. Chem. Lett., March 11, 2022 AstraZeneca, Gothenburg, SE
Reviewer: